Cancer rates are declining, but young women are being diagnosed more frequently. Learn about the current trends and research ...

As January, a month dedicated to cervical cancer, winds down, an expert talks about how motherhood can still be a possibility ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

The median overall survival (OS) of people with recurrent, advanced endometrial cancer is reported to be less than three years when treated with chemo alone. The decision comes around two years ...

Alarming new trend: younger adults under 50 are being diagnosed with cancer in unprecedented numbers. Find out why young ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

Advances in cancer treatment have considerably increased survival rates but for women of reproductive age, the impact on fertility is a major worry. Fertility preservation provides hope to women ...

Recent trends reveal a sharp rise in cancer cases in India, with younger patients and a lack of effective screening programs ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Cancer mortality has increased in the last decade, with 8,140 cases compared to 6,278 in 2014. The report 'The figures of ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...